Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 103

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 103
---
 primarily of net product sales of our commercial products in the U.S., supplemented by royalty and licensing revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three and six months ended months ended June 30, 2025 (dollars in thousands):Three Months Ended June 30,ChangeSix Months EndedJune 30,Change20252024AmountPercent20252024AmountPercentNet product salesQelbree$77,547 $59,395 $18,152 31%$142,292 $104,499 $37,793 36%GOCOVRI36,660 31,703 4,957 16%67,349 58,265 9,084 16%APOKYN12,820 17,295 (4,475)(26)%27,796 33,944 (6,148)(18)%Trokendi XR11,193 17,086 (5,893)(34)%23,994 33,075 (9,081)(27)%Oxtellar XR11,637 29,516 (17,879)(61)%21,835 56,459 (34,624)(61)%ONAPGO1,604 — 1,604 100 %1,604 — 1,604 100 %Other(1)6,534 7,543 (1,009)(13)%15,113 14,757 356 2%Total net product sales157,995 162,538 (4,543)(3)%299,983 300,999 (1,016)—%Royalty, licensing and other revenues7,458 5,787 1,671 29%15,294 10,970 4,324 39%Total revenues$165,453 $168,325 $(2,872)(2)%$315,277 $311,969 $3,308 1%___________________________________________

(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.

Net Product Sales

Net product sales were $158.0 million and $162.5 million for the three months ended June 30, 2025 and 2024, respectively. Net product sales were $300.0 million and $301.0 million for the six months ended June 30, 2025 and